Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087802
Status:
COMPLETED
Last Update Posted:
2009-04-16
First Post:
2004-07-13
Brief Title:
GemcitabineOxaliplatin GEMOX vs CarboplatinPaclitaxel CP in Non-Small Cell Lung Cancer NSCLC
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Phase III Randomized Trial of GemcitabineOxaliplatin GEMOX Versus CarboplatinPaclitaxel CP as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare combination treatment of gemcitabine oxaliplatin GEMOX with carboplatin paclitaxel CP to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SR96669 | None | None | None |